»
Comprehensive Biomaterials
 
 

Comprehensive Biomaterials, 1st Edition

 
Comprehensive Biomaterials, 1st Edition,Paul Ducheyne,Paul Ducheyne,Kevin Healy,Dietmar E. Hutmacher,David W. Grainger,C. James Kirkpatrick,ISBN9780080552941
 
 
 

Ducheyne   &   Ducheyne   &   Healy   &   Hutmacher   &   Grainger   &   Kirkpatrick   

Elsevier Science

9780080552941

3672

The new standard reference for students and researchers interested in any aspect of biomaterials science and engineering.

eBook
eBook Overview

PDF format

VST (VitalSource Bookshelf) format

USD 4,130.00
Add to Cart
 
 

Key Features

      • Reviews the current status of nearly all biomaterials in the field by analyzing their strengths and weaknesses, performance as well as future prospects
      • Presents appropriate analytical methods and testing procedures in addition to potential device applications
      • Provides strategic insights for those working on diverse application areas such as R&D, regulatory management, and commercial development

      Description

      Comprehensive Biomaterials brings together the myriad facets of biomaterials into one, major series of six edited volumes that would cover the field of biomaterials in a major, extensive fashion: • Volume 1: Metallic, Ceramic and Polymeric Biomaterials • Volume 2: Biologically Inspired and Biomolecular Materials • Volume 3: Methods of Analysis • Volume 4: Biocompatibility, Surface Engineering, and Delivery Of Drugs, Genes and Other Molecules • Volume 5: Tissue and Organ Engineering • Volume 6: Biomaterials and Clinical Use Experts from around the world in hundreds of related biomaterials areas have contributed to this publication, resulting in a continuum of rich information appropriate for many audiences. The work addresses the current status of nearly all biomaterials in the field, their strengths and weaknesses, their future prospects, appropriate analytical methods and testing, device applications and performance, emerging candidate materials as competitors and disruptive technologies, and strategic insights for those entering and operational in diverse biomaterials applications, research and development, regulatory management, and commercial aspects. From the outset, the goal was to review materials in the context of medical devices and tissue properties, biocompatibility and surface analysis, tissue engineering and controlled release. It was also the intent both, to focus on material properties from the perspectives of therapeutic and diagnostic use, and to address questions relevant to state-of-the-art research endeavors.

      Readership

      This work is of interest to any student, researcher or engineer working in biomaterials, medicinal research, cell biology, tissue engineering, tissue physiology, regenerative medicine, microfabrication, and biomedical devices and applications.

      Paul Ducheyne

      Paul Ducheyne is Professor of Bioengineering and Professor of Orthopaedic Surgery Research at the University of Pennsylvania, Philadelphia, USA. He is the Director of its Center for Bioactive Materials and Tissue Engineering. He also is Special Guest Professor at the University of Leuven, Belgium. Paul Ducheyne has Materials Science and Engineering degrees from the K.U. Leuven. Belgium (M.Sc.: 1972; Ph.D.: 1976). With fellowships from the National Institutes of Health (International Postdoctoral Fellowship) and the Belgian American Educational Foundation (Honorary Fellowship), he performed postdoctoral research at the University of Florida. Paul Ducheyne has organized a number of symposia and meetings, such as the Fourth European Conference on Biomaterials (1983), the Engineering Foundation Conference on Bioceramics (1986) which led to the New York Academy of Sciences publication: "Bioceramics, material characteristics versus in vivo behavior", and the Sixth International Symposium on Ceramics in Medicine (1993). He has lectured around the world and serves or has served on the editorial board of more than ten scientific journals in the biomaterials, bioceramics, bioengineering, tissue engineering, orthopaedics and dental fields. He has been a member of the editorial board, and then an associate editor of Biomaterials, the leading biomaterials journal, since its inception in the late seventies. He has authored more than 300 papers and chapters in a variety of international journals and books, and he has edited 10 books. He has also been granted more than 40 US patents with international counterparts. His papers have been cited about 7000 times; his ten most visible papers have been cited more than 2000 times. Paul Ducheyne started his career in Europe. While at the K.U. Leuven, Belgium (1977 - 1983), he was one of the co-founders of the Post-Graduate Curriculum in Bioengineering. This program is now a full M.Sc. program in the School of Engineering and Applied Sciences. In those initial years, he was also chairman-founder of the chapter on Biomedical Engineering of the Belgian Engineering Society (Flemish section) and director of Meditek, the Flemish Government body created to promote Academia to Industry Technology Transfer in the area of Biomedical Engineering. Paul Ducheyne founded Gentis, Inc., which focuses on breakthrough concepts for spinal disorders. Previously, he founded Orthovita (NASDAQ: VITA) in 1992 and served as Chairman of its Board of Directors until 1999. Orthovita focuses on bioceramic implant materials for orthopaedics. Paul Ducheyne has been secretary of the European Society for Biomaterials, is Past President of the Society for Biomaterials (USA) and Past President of the International Society for Ceramics in Medicine. He has been recognized as a fellow of the American Association for the Advancement of Science (AAAS), fellow of the American Institute of Medical and Biological Engineering (AIMBE), and fellow of the International Association of Biomaterials Societies. He was the first Nanyang Visiting Professor at the Nanyang Institute of Technology, Singapore and he has received the C. William Hall Award from the Society for Biomaterials. Many of Paul Ducheyne's trainees have become leaders of the next generation. Among his trainees are professors at the University of California at Berkeley, the University of Michigan, Columbia University, Georgia Institute of Technology, the K.U. Leuven (Belgium), etc... Among the six U.S. Associate Editors of the Journal for Biomedical Materials Research (the Journal of the Society for Biomaterials), three were his PhD students.

      Affiliations and Expertise

      University of Pennsylvania, Philadelphia, PA, USA

      Information about this author is currently not available.

      Kevin Healy

      Kevin E. Healy, Ph.D. is the Jan Fandrianto Distinguished Professor in Engineering at the University of California at Berkeley in the Departments of Bioengineering and Materials Science and Engineering. He received a Bachelor of Science degree from the University of Rochester in Chemical Engineering in 1983. In 1985 he received a Masters of Science degree in Bioengineering from the University of Pennsylvania, and in 1990 he received a Ph.D. in Bioengineering also from the University of Pennsylvania. He was elected a Fellow of the American Institute of Medical and Biological Engineering in 2001. He has authored or co-authored more than 200 published articles, abstracts, or book chapters which emphasize the relationship between materials and the tissues they contact. His research interests include the design and synthesis of biomimetic materials that actively direct the fate of embryonic and adult stem cells, and facilitate regeneration of damaged tissues and organs. Major discoveries from his laboratory have centered on the control of cell fate and tissue formation in contract with materials that are tunable in both their biological content and mechanical properties. These materials find applications in medicine, dentistry, and biotechnology. He is currently an Associate Editor of the Journal of Biomedical Materials Research. He has served on numerous panels and grant review study sections for N.I.H. He has given more than 200 invited lectures in the fields of Biomedical Engineering and Biomaterials. He is a named inventor on numerous issued United States and international patents relating to biomaterials, and has founded several companies to develop materials for applications in biotechnology and regenerative medicine.

      Affiliations and Expertise

      University of California, Berkeley, Berkeley, CA, USA

      Dietmar E. Hutmacher

      Professor Dietmar W. Hutmacher holds an accomplished international profile and strong research focus in the field of biomaterials, tissue engineering and regenerative medicine. Outcomes from Prof. Hutmacher's research have resulted in high profile scientific and academic contributions as well as patents and commercialization. He was named as one of the world's top materials scientist by Thomson Reuters in 2010 (ranked 45 out of the top 100). Prof. Hutmacher's track record shows that he has successfully mastered the main challenge in the biomedical sciences field, namely to cross traditional boundaries to nurture and initiate research and educational programs across different disciplines, particularly within engineering, biology and medicine.

      Affiliations and Expertise

      Queensland University of Technology, Brisbane, QLD, Australia

      David W. Grainger

      David W. Grainger is the George S. and Dolores Doré Eccles Presidential Endowed Chair in Pharmaceutics and Pharmaceutical Chemistry, Chair of the Department of Pharmaceutics and Pharmaceutical Chemistry, and Professor of Bioengineering at the University of Utah. Grainger received his Ph.D. in Pharmaceutical Chemistry from the University of Utah in 1987 studying blood-compatible polymers, particularly block copolymers functionalized with heparin blocks and their coatings. He then received an Alexander von Humboldt Fellowship to perform postdoctoral research under Prof. Helmut Ringsdorf, University of Mainz, Germany. This training initiated over 25 years of experience with various aspects of developing "materials in medicine". Grainger's research expertise is focused on improving implanted medical device performance, drug delivery of new therapeutic proteins, nucleic acids and live vaccines, nanomaterials interactions with human tissues, low-infection biomaterials, and innovating diagnostic devices based on DNA and protein biomarker capture. Additionally, he is an expert in applications of surface analytical methods to biomedical interfaces, including difficult surface patterns and nanomaterials, and perfluorinated biomaterials. Grainger has published over 130 full research papers at the interface of materials innovation in medicine and biotechnology, and novel surface chemistry. He has won research several awards, including the prestigious 2007 Clemson Award for Basic Research, Society for Biomaterials, and the 2005 American Pharmaceutical Research and Manufacturer's Association's award for "Excellence in Pharmaceutics". He won a short-term visiting professorship in Tokyo from the Japanese Society for the Promotion of Science, and a CNRS Visiting Professorship in Paris, France. He has also received several teaching awards for outstanding mentoring and teaching service, including the University of Utah 2010 Distinguished Postdoctoral and Graduate Student Mentoring Award, the US West/Qwest Faculty Education Excellence Award (Colorado State University, 2000), Colorado State University College of Natural Sciences "Undergraduate Teacher of the Year", 2000, Colorado State University Alumni Association "Teacher of the Year", 2002, and several "Favorite Faculty" Awards from CSU Undergraduate Student Associations. Grainger delivered the EU Madame Curie guest lectures at the Technical University-Aachen, Germany in 2009 and the 15th Annual Fritz Straumann lecture, AO Foundation, Davos, Switzerland, December, 2008. Grainger is an elected Fellow of both the American Association for the Advancement of Science (AAAS) and the American Institute of Medical and Biological Engineering (AIMBE), and Inducted Honorary Fellow, International Union of the Societies of Biomaterials Science and Engineering, 2008. He has organized 23 international scientific symposia including the prestigious Gordon Research Conference in Biomaterials, presented over 320 hundred invited talks all over the world. He serves on editorial boards for 4 major research journals in the biomedical materials field, reviewing over 50 manuscripts annually. He is Chair and standing member of Emerging Bioanalytical Technologies scientific review group (SRG) at NIH, past standing member on the NIH's Surgery and Bioengineering SRG, and over 20 other NIH and NSF review panels, some as chair. Additionally, he serves on the Scientific Advisory Boards of the Univ. Wisconsin-Madison NSF MRSEC on High Performance Nanostructured Materials, the NIH P41 National Research Center at the University of Washington (NESAC/Bio) for surface analysis for biomedical problems, NSF Harvard/New Mexico NSF PREM MRSEC, and several international research foundations (AO Foundation, Davos, Switzerland, Swiss Center for Materials Competence, Zurich, the Willem S. Kolff Institute, Royal University

      Affiliations and Expertise

      University of Utah, Salt Lake City, UT, USA

      C. James Kirkpatrick

      C. James Kirkpatrick is currently Professor of Pathology and Chairman of the Institute of Pathology at the Johannes Gutenberg University of Mainz, Germany, having taken up this position in 1993. He is also Honorary Professor at both the Peking Union Medical College, Beijing and the Sichuan University, Chengdu in China. Kirkpatrick is a graduate of the Queen's University of Belfast and holds a triple doctorate in science and medicine (PhD: 1977; MD: 1982; DSc: 1992). Previous appointments were in pathology at the University of Ulm, where he did post-doctoral research in experimental pathology, Manchester University (Lecturer in Histopathology) and the RWTH Aachen (Professor of Pathology & Electron Microscopy). On moving to Aachen in 1987 he established a cell culture laboratory which began using modern methods of cell and molecular biology to study how human cells react to biomaterials. Since then his principal research interests continue to be in the field of biomaterials in tissue engineering and regenerative medicine, with special focus on the development of human cell culture techniques, including novel 3D coculture methodology for biomaterials. His research laboratory, the REPAIR-lab, is a member of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, and his research is principally funded by the EU, BMBF (German Federal Ministry of Education and Research), BMVg (German Federal Ministry of Defence) and the DFG (German Research Foundation). This emphasis on developing sophisticated in vitro techniques has brought him the Research Prize of the State of Rhineland-Palatinate for Research on Replacement and Alternative Methods for Animal Research. In 2010 he received, as first medical graduate, the Chapman Medal from the Institute of Materials, Minerals & Mining in London for "distinguished research in the field of biomedical materials". He is author/coauthor of more than 380 publications in peer-reviewed journals and has made more than 1000 presentations to scientific meetings worldwide. He is a former President of both the German Society for Biomaterials (2001-2005) and the European Society for Biomaterials (2002-2007; George Winter Award 2008) and has served on the Council of the latter since 1995. Kirkpatrick is a long-standing member of the Editorial Board of the premier journal Biomaterials and is a current Associate Editor (since 2002). He has also served as Associate Editor of the leading Journal of Pathology (2001-2006). In total, he serves or has served as an Editorial Board member of 18 international journals in pathology, biomaterials and tissue engineering. Kirkpatrick is a member of the Scientific Advisory Board of a number of research institutes, centres of excellence and companies in biomaterials and regenerative medicine in Europe, as well as the Medical Technology Committee, Federal Ministry of Education & Research in Germany (BMBF) (since 2005) and the German Federal Institute for Drugs & Medical Devices (BfArM)(since 2007). During his entire research career, Kirkpatrick has actively practiced diagnostic histopathology, which has allowed him to apply modern molecular pathology techniques to the study of biofunctionality of biomaterials. Since 1997 he is a Fellow of the Royal College of Pathologists, London and since 1995 a Fellow of Biomaterials Science & Engineering (FBSE) of the IUS-BSE (International Union of Societies for Biomaterials Science & Engineering). He is also in a second term of service on the Council of the European Chapter of the Tissue Engineering & Regenerative Medicine International Society (TERMIS-EU). Kirkpatrick had also had the privilege of chairing the Scientific Programme Committee for the 8th World Biomaterials Congress in Amsterdam in 2008.

      Affiliations and Expertise

      Johannes Gutenburg University Medical Center, Mainz, Germany

      Comprehensive Biomaterials, 1st Edition

      Editor-in-Chief

      Co-Editors

      Editor-in-Chief Biography

      Co-Editor Biographies

      Preface

      Foreword

      Permission Acknowledgments

      1.101. Biomaterials

      1.102. Metals for Use in Medicine

      Abbreviations

      1.102.1. Introduction

      1.102.2. General Requirements for Long-Term Implantation

      1.102.3. Key Metallurgy Concepts

      1.102.4. Chemical Composition and Structure

      1.102.5. Mechanical Properties

      1.102.6. Processing Effects

      1.102.7. Future Developments

      1.102.8. Summary

      1.103. Electrochemical Behavior of Metals in the Biological Milieu

      Abbreviations

      Acknowledgments

      1.103.1. Introduction

      1.103.2. Metals Currently Used in Medical Devices

      1.103.3. Metallic Biocompatibility

      1.103.4. The Biological Milieu

      1.103.5. Basic Electrochemistry Concepts

      1.103.6. Passive Oxide Films and Semiconducting Electrochemistry

      1.103.7. Electrical Double Layer

      1.103.8. Electrochemical Impedance Spectroscopy (EIS) of Metallic Biomaterials

      1.103.9. Mechanically Assisted Corrosion

      1.103.10. Effects of Prior Electrochemical History

      1.103.11. Oxide Film Structure and Formation

      1.103.12. Effects of Solution Redox System

      1.103.13. Biological Consequences: Oxidation and Reduction

      1.103.14. Summary

      1.103.15. Appendix: Derivation of Mott–Schottky Equation

      1.104. Shape Memory Alloys for Use in Medicine

      Abbreviations

      1.104.1. Introduction

      1.104.2. Fundamentals of Shape Memory Systems

      1.104.3. Practical SMAs

      1.104.4. Manufacturing, Processing, and Performance of Nitinol

      1.104.5. Minimally Invasive Device Applications for Nitinol

      1.104.6. Orthodontic Applications for Nitinol

      1.104.7. Orthopedic Applications for Nitinol

      1.104.8. Clinical Imaging of Nitinol Medical Devices

      1.104.9. Long-Term Durability and Biocompatibility of Nitinol

      1.104.10. Summary and Future Directions

      1.105. Alumina

      Abbreviations

      1.105.1. Introduction

      1.105.2. Properties of Alumina

      1.105.3. Clinical Application of Alumina Ceramics

      1.106. Zirconia as a Biomaterial

      Abbreviations

      1.106.1. Introduction

      1.106.2. Crystallography and Phase Transformation of Zirconia

      1.106.3. Different Types of Zirconia and Zirconia-Based Composites

      1.106.4. The Use of Zirconia as a Biomaterial: Current State of the Art

      1.106.5. Future Directions

      1.106.6. Conclusion

      1.106.7. Further Reading

      1.107. Carbon and Diamond

      Abbreviations

      1.107.1. Introduction

      1.107.2. Pyrolytic Carbon

      1.107.3. Diamond-Like Carbon

      1.107.4. Microcrystalline, Nanocrystalline, and Ultrananocrystalline Diamond

      1.107.5. Summary of Carbon and Diamond

      1.108. Wear-Resistant Ceramic Films and Coatings

      Abbreviations

      1.108.1. Introduction

      1.108.2. State of the Art – Processing, Microstructure, Biocompatibility, and Mechanical Properties of Ceramic Coatings

      1.108.3. Future Trends

      1.109. Bioactive Ceramics

      Abbreviations

      1.109.1. Bioactivity

      1.109.2. Bone Formation at the Interface with Bioactive Materials

      1.109.3. Testing Bioactivity In Vitro

      1.109.4. Methods of Analysis of the Dissolution–Precipitation Reaction

      1.109.5. Bioactive Glasses

      1.109.6. Bioactive Glass Ceramics

      1.109.7. Calcium Phosphate Ceramics

      1.109.8. Silica-Calcium Phosphate Nanocomposite

      1.109.9. Silica-Xerogel

      1.109.10. Conclusion

      1.110. Bioactive Glass-Ceramics

      Abbreviations

      1.110.1. AW Glass-Ceramic

      1.110.2. Apatite–Mica Glass-Ceramics

      1.110.3. Apatite–Mullite Glass-Ceramics

      1.112. Calcium Phosphate Coatings

      1.112.1. Introduction

      1.112.2. Calcium Phosphates

      1.112.3. Titanium Implants

      1.112.4. Plasma Spraying of CaP Coatings

      1.112.5. Electrochemical Deposition of CaP Coatings

      1.112.6. Biomimetic CaP Coatings

      1.112.7. Conclusion and Perspectives

      1.113. Bioactive Layer Formation on Metals and Polymers

      Abbreviations

      1.113.1. Introduction

      1.113.2. Bioactive Layers

      1.113.3. Future Perspectives

      1.113.4. Additional Reading

      1.114. Bioactivity: Mechanisms

      Abbreviations

      Acknowledgments

      1.114.1. Introduction

      1.114.2. Mechanisms of Bioactive Behavior

      1.114.3. Mechanisms of Biodegradation of Bioactive Ceramics

      1.114.4. Summary

      1.115. Calcium Phosphates for Cell Transfection

      Abbreviations

      1.115.1. Introduction

      1.115.2. Applications of Bioceramic Cell Transfection

      1.115.3. The Role of Bioceramic Characteristics for their Applications

      1.115.4. Traditional Use of Calcium Phosphate for Cell Transfection

      1.115.5. Hydroxylapatite Ceramics for Cell Transfection

      1.115.6. Perspectives and Material Evolution

      1.116. Bioactive Ceramics: Cements

      Abbreviations

      1.116.1. Introduction

      1.116.2. Calcium Sulfate

      1.116.3. Portland Cement and MTA

      1.116.4. Apatite Cement

      1.116.5. Brushite Cement

      1.116.6. Future Direction

      1.117. Phosphate-Based Glasses

      Abbreviations

      1.117.1. Phosphate Glasses: Physical Properties and Processing

      1.117.2. Biological Properties of Phosphate Glasses

      1.117.3. Therapeutic Actions of Phosphate Glasses

      1.118. Calcium Phosphate Ceramics with Inorganic Additives

      Abbreviations

      1.118.1. Introduction

      1.118.2. Bone

      1.118.3. Current Methods in Bone Regeneration

      1.118.4. Improvement of Synthetic Bone Graft Substitutes

      1.118.5. Trace Elements in Bone Metabolism and Processes Related to Bone Formation

      1.118.6. Inorganic Additives in Calcium Phosphate Ceramics

      1.118.7. Future Perspectives

      1.119. Silicon-Containing Apatites

      Abbreviations

      1.119.1. Introduction

      1.119.2. Synthesis and Characterization of Silicon-Containing Apatites

      1.119.3. In Vitro and In Vivo Studies

      1.119.4. Mechanisms of Enhanced Biological Response

      1.119.5. Other Silicon-Containing Calcium Phosphate Ceramics

      1.119.6. Conclusions and Future Directions

      1.120. Synthetic Bone Grafts: Clinical Use

      Abbreviations

      1.120.1. Introduction

      1.120.2. A Brief History of Bone Grafts

      1.120.3. Synthetic Bone Graft Substitutes

      1.120.4. Conclusion

      1.121. Polymer Fundamentals: Polymer Synthesis

      1.121.1. Introduction to Polymer Science

      1.121.2. Polycondensation

      1.121.3. Addition Polymerization

      1.121.4. Polymer Reactions

      1.121.5. Conclusion

      1.122. Structural Biomedical Polymers (Nondegradable)

      1.122.1. Historical Overview

      1.122.2. Classifications of Medical Polymers and Their Applications

      1.122.3. Designing Structural Implants with Polymers

      1.122.4. Summary

      1.123. Degradable Polymers

      Abbreviations

      1.123.1. Introduction

      1.123.2. Overview of PLGA Copolymers

      1.123.3. Parameters Affecting Degradation Rate of PLGA

      1.123.4. Biocompatibility of PLGA

      1.123.5. Applications of PLGA Across Length Scales

      1.123.6. Rationale for Development of PPEs

      1.123.7. Structure–Function Relationships of PPEs

      1.123.8. Toxicity and Biocompatibility of PPEs

      1.123.9. Design of PPE Drug Carriers

      1.123.10. Design of Thermoresponsive PPEs

      1.123.11. Design of PPE and PPA Gene Carriers

      1.123.12. Conclusion

      1.124. Polymer Films Using LbL Self-Assembly

      Abbreviations

      1.124.1. Introduction: Strategies for Surface Modification with Polymers

      1.124.2. Fundamentals of Multilayer Formation: LbL Thin Films

      1.124.3. Conclusions

      1.126. Shape-Memory Polymers

      Abbreviations

      1.126.1. Fundamental Principles of Shape-Memory Polymers and of the Quantification of Shape-Memory Properties

      1.126.2. Synthesis and Properties of Selected Examples of SMP Intended for Biomedical Applications

      1.126.3. Multifunctional SMPs by Integrating Hydrolytic Degradability or Controlled Drug Release Capability

      1.126.4. Biomedical Applications of SMPs

      1.127. Electrospinning and Polymer Nanofibers: Process Fundamentals

      Abbreviations

      1.127.1. Introduction

      1.127.2. Process Description

      1.127.3. Mechanics: Electrostatics and Hydrodynamics

      1.127.4. Products of Electrospinning

      1.127.5. Summary and Conclusion

      1.128. Fluorinated Biomaterials

      Abbreviations

      Acknowledgments

      1.128.1. Introduction

      1.128.2. Fluorinated Polymer Chemical and Physical Properties

      1.128.3. Fluoropolymers

      1.128.4. Biomedical Applications of Fluorinated Biomaterials

      1.128.5. Conclusion and Perspectives

      1.129. Engineering the Biophysical Properties of Basement Membranes into Biomaterials: Fabrication and Effects on Cell Behavior

      Abbreviations

      Acknowledgments

      1.129.1. Introduction

      1.129.2. Basement Membrane

      1.129.3. Nanostructure Fabrication

      1.129.4. Cellular Response to Topographic Cues with Dimensions from Nano- to Micron-Scales

      1.130. Electroactive Polymeric Biomaterials

      Abbreviations

      Acknowledgments

      1.130.1. Introduction

      1.130.2. Conjugated Polymer Electrode Coatings

      1.130.3. Conjugated Polymers on Devices

      1.130.4. Implantable Modification of Conjugated Polymers

      1.130.5. Conjugated Polymer-Based Drug Delivery

      1.130.6. Synthesis of Conducting Polymers In Vivo

      1.130.7. Summary and Future Outlook

      1.131. Superporous Hydrogels for Drug Delivery Systems

      Abbreviations

      1.131.1. Introduction

      1.131.2. Hydrogels in Drug Delivery

      1.131.3. Superporous Hydrogels

      1.131.4. SPH Synthesis

      1.131.5. SPH Properties

      1.131.6. SPH Generations

      1.131.7. SPH Scale Up

      1.131.8. SPH Stability

      1.131.9. SPH Safety

      1.131.10. SPH Platform Design for Drug Delivery

      1.131.11. SPH in Drug Delivery and Other Areas

      1.131.12. Conclusions

      1.132. Dynamic Hydrogels

      Abbreviations

      1.132.1. Introduction

      1.132.2. Functional Modes/General Dynamic Mechanisms

      1.132.3. Specific Stimuli and Response Mechanisms

      1.132.4. Biomedical Applications

      1.132.5. Future Directions

      2.201. Bio-inspired Silica Nanomaterials for Biomedical Applications

      Abbreviations

      Acknowledgment

      2.201.1. Introduction

      2.201.2. Biosilicification

      2.201.3. Bio-inspired Silica Synthesis for Biomedical Applications

      2.201.4. Perspectives and Challenges

      2.201.5. Conclusion

      2.202. Engineering Viruses For Gene Therapy

      Abbreviations

      2.202.1. Introduction

      2.202.2. Viral Engineering

      2.202.3. Design of Artificial Viruses

      2.202.4. Conclusions and Future Work

      2.203. Protein-Engineered Biomaterials: Synthesis and Characterization

      Abbreviations

      2.203.1. Introduction

      2.203.2. Rational Design and Modular Building Blocks

      2.203.3. Synthesis and Purification

      2.203.4. Postsynthesis Materials Processing

      2.203.5. Characterization

      2.203.6. Biological Interactions and Immunogenicity

      2.203.7. Future Directions and Conclusions

      2.204. Peptoids: Synthesis, Characterization, and Nanostructures

      Abbreviations

      2.204.1. Introduction

      2.204.2. Synthesis

      2.204.3. Peptoid Structure and Characterization

      2.204.4. Combinatorial Discovery of Peptoid Ligands

      2.204.5. Drug Discovery

      2.204.6. Cellular Delivery/Uptake Vectors

      2.204.7. Biomimetic Materials

      2.204.8. Summary and Future Directions

      2.205. Self-Assembling Biomaterials

      Abbreviations

      2.205.1. Introduction

      2.205.2. Planar Self-Assembling Systems

      2.205.3. 3D Self-Assembling Systems

      2.205.4. Modulating the Mechanics of Self-Assembling Systems

      2.205.5. Advantages Provided by Self-Assembled Systems for Biomaterials Applications

      2.205.6. Immune and Inflammatory Responses to Self-Assembling Materials

      2.205.7. In vivo Applications of Self-Assembled Biomaterials

      2.205.8. Concluding Remarks

      2.206. Phages as Tools for Functional Nanomaterials Development

      Abbreviations

      2.206.1. Introduction

      2.206.2. Phages for Inorganic–Organic Hybrid Materials

      2.206.3. Phage for Energy Materials

      2.206.4. Phage for Sensing Materials

      2.206.5. Phage for Biomedical Application

      2.206.6. Summary and Future Perspectives

      2.207. Extracellular Matrix: Inspired Biomaterials

      Abbreviations

      2.207.1. Introduction

      2.207.2. Overview of ECM Structure and Function

      2.207.3. Types of ECM Mimicry

      2.207.4. Future Directions

      2.208. Artificial Extracellular Matrices to Functionalize Biomaterial Surfaces

      Abbreviations

      2.208.1. Introduction

      2.208.2. Components to Be Used for aECM

      2.208.3. Biological Interaction Profiles of aECM and Their Components

      2.208.4. Preparation and Structure of aECM

      2.208.5. Biochemical Characterization of aECM

      2.208.6. Immobilization of aECM

      2.208.7. Cell Biological Effects of aECM

      2.208.8. Results from Animal Experiments

      2.208.9. Conclusions and Outlook

      2.209. Materials as Artificial Stem Cell Microenvironments

      Abbreviations

      2.209.1. Introduction

      2.209.2. The Adult Stem Cell and Its Niche

      2.209.3. Naturally Derived ECM Components for In Vitro Stem Cell Manipulation

      2.209.4. Engineered Substrates as Artificial Stem Cell Niches

      2.209.5. Topographically Patterned Substrates as Versatile Stem Cell Microenvironments

      2.209.6. Biomaterials Approaches to Emulate Stem Cell Niches in 3D

      2.209.7. Conclusions

      2.210. Bone as a Material

      Abbreviations

      2.210.1. Introduction

      2.210.2. Bone Composition

      2.210.3. Bone Formation

      2.210.4. Bone Structure and Hierarchical Organization

      2.210.5. Bone Mechanical Behavior

      2.210.6. Bone as a Dynamic Adaptive Material

      2.210.7. Bone as a Material During Disease and Drug Treatment

      2.210.8. Conclusion

      2.211. Polymers of Biological Origin

      Abbreviations

      2.211.1. Introduction

      2.211.2. Natural-Based Polymeric Systems

      2.211.3. Processing of TE Scaffolds

      2.211.4. Cell Encapsulation in Injectable Biodegradable Hydrogels for TE Applications

      2.211.5. Final Remarks

      2.212. Silk Biomaterials

      Acknowledgments

      2.212.1. Overview

      2.212.2. Silk Film Biomaterials

      2.212.3. Silk Sponge Scaffold Biomaterials

      2.212.4. Silk Nanofiber Biomaterials

      2.212.5. Silk Hydrogel Biomaterials

      2.212.6. Silk Microsphere and Nanoparticle Biomaterials

      2.212.7. Silk Optical Biomaterials

      2.212.8. Other Silk Materials

      2.212.9. Conclusions

      2.213. Chitosan

      Abbreviations

      2.213.1. Sources, Analysis, and Properties

      2.213.2. Processing

      2.213.3. Biomedical Applications

      2.213.4. Future Prospects

      2.214. Hyaluronic Acid

      Abbreviations

      Acknowledgments

      2.214.1. Introduction

      2.214.2. Production of HA

      2.214.3. Analysis and Industry Standards

      2.214.4. Chemical Modification of HA

      2.214.5. Medical Applications of HA

      2.214.6. Future Perspectives and Conclusions

      2.215. Collagen: Materials Analysis and Implant Uses

      Abbreviations

      Acknowledgments

      2.215.1. Origins of Collagen and Role in Animal Physiology

      2.215.2. The Biochemical Fingerprint of Collagen

      2.215.3. Sources of Collagen

      2.215.4. Collagen: Purification and Analysis

      2.215.5. Biomedical Applications of Collagen

      2.215.6. Outlook and Future for Collagen Materials

      2.216. Collagen–GAG Materials

      Abbreviations

      2.216.1. Introduction

      2.216.2. Fabrication of Collagen–GAG Materials

      2.216.3. Characterization of Collagen–GAG Materials

      2.216.4. In Vitro Applications

      2.216.5. In Vivo Applications

      2.216.6. Conclusions

      2.217. Fibrin

      Abbreviations

      2.217.1. Historical Perspective

      2.217.2. Composition, Structure, and Properties

      2.217.3. Fibrin Use as a Delivery System

      2.217.4. Fibrin in Tissue Engineering Applications

      2.217.5. Fibrin in Clinical Practice

      2.217.6. Conclusion

      2.218. Elastin Biopolymers

      Abbreviations

      2.218.1. Recombinant Human Tropoelastin-Based Constructs

      2.218.2. The Elastin-Like Recombinamers

      2.218.3. Animal-Derived Solubilized Elastin

      2.219. Biophysical Analysis of Amyloid Formation

      Abbreviations

      Acknowledgments

      2.219.1. Introduction

      2.219.2. Monomer Folding

      2.219.3. Aggregation Intermediates

      2.219.4. Mature Amyloid Fibrils

      2.219.5. Conclusion

      2.220. Extracellular Matrix as Biomimetic Biomaterial: Biological Matrices for Tissue Regeneration

      Abbreviations

      2.220.1. Extracellular Matrix

      2.220.2. Materials Applied in TE

      2.220.3. Induction of Graft Vascularization

      2.220.4. Biological Vascularized Scaffold

      2.220.5. Summary and Future Directions

      2.221. Decellularized Scaffolds

      Abbreviations

      2.221.1. Introduction

      2.221.2. Decellularization Methodology

      2.221.3. Origin of Decellularized Scaffolds and their Applications

      2.221.4. Concluding Remarks

      2.223. Bacterial Cellulose as Biomaterial

      Abbreviations

      2.223.1. Introduction

      2.223.2. Bacterial Cellulose: Growth

      2.223.3. Modification of Nanostructure

      2.223.4. Engineering of Morphology

      2.223.5. Shaping in 3D Structure

      2.223.6. Biocompatibility

      2.223.7. Biomechanics

      2.223.8. Cell Interactions and Migration

      2.223.9. Biomedical Applications

      2.223.10. Future Outlook

      3.301. Surface Analysis and Biointerfaces: Vacuum and Ambient In Situ Techniques

      Abbreviations

      Acknowledgments

      3.301.1. Introduction

      3.301.2. Ambient Analytical Methods

      3.301.3. Ultrahigh Vacuum Surface Analytical Techniques

      3.301.4. Next Challenges: Nanomaterial Surfaces

      3.301.5. Conclusions

      3.302. Atomic Force Microscopy

      Abbreviations

      3.302.1. Introduction

      3.302.2. Fundamentals of the AFM

      3.302.3. Force–Distance Measurement and Force Mapping

      3.302.4. Nanoindentation and Measurement of Near-Surface Nanomechanical Properties of Polymeric Biomaterials

      3.302.5. Probing Molecular Interaction and Recognition Sites on Biosurfaces

      3.302.6. Limitations and Perspectives

      3.303. Proteomic and Advanced Biochemical Techniques to Study Protein Adsorption

      Abbreviations

      3.303.1. Introduction

      3.303.2. Unbiased Analysis of Adsorbed Proteins by Polyacrylamide Gel Electrophoresis

      3.303.3. Analysis of Adsorbed Proteins by 2DPAGE

      3.303.4. Quantification of Protein Amounts by Mass Spectrometry

      3.303.5. Proteomics to Study Protein Denaturation on Surfaces

      3.303.6. Challenges of the Proteomics Approach

      3.303.7. Conclusions

      3.304. Developments in High-Resolution CT: Studying Bioregeneration by Hard X-ray Synchrotron-Based Microtomography

      Abbreviations

      Acknowledgments

      3.304.1. Hard X-ray Microimaging

      3.304.2. Comparative Animal Study of Bioceramic-Supported Bone Regeneration

      3.304.3. Bone Regeneration After Sinus Floor Augmentation in Humans

      3.304.4. Summary

      3.305. Biomedical Thin Films: Mechanical Properties

      Abbreviations

      Acknowledgments

      3.305.1. Introduction

      3.305.2. Coating Techniques

      3.305.3. Thin Film Mechanical Testing: Methods

      3.305.4. Concluding Remarks

      3.306. Microindentation

      Abbreviations

      3.306.1. Introduction

      3.306.2. Overview of Nanoindentation Technique

      3.306.3. Application of Nanoindentation to Biomaterials

      3.306.4. Summary

      3.307. Finite Element Analysis in Bone Research: A Computational Method Relating Structure to Mechanical Function

      Abbreviations

      3.307.1. Introduction

      3.307.2. Macroscale: Whole Bone

      3.307.3. Mesoscale: Trabecular Bone

      3.307.4. Microscale: Ultrastructural Features

      3.307.5. Nanoscale: Mineral and Collagen

      3.307.6. Conclusions and Future Directions

      3.308. The Mechanics of Native and Engineered Cardiac Soft Tissues

      Abbreviations

      Acknowledgment

      3.308.1. Introduction

      3.308.2. Heart Valve Tissues

      3.308.3. Myocardium

      3.308.4. Constitutive Models of Soft Tissues

      3.308.5. Emulating Native Tissue Mechanical Behavior in Engineered Tissues

      3.309. Fluid Mechanics: Transport and Diffusion Analyses as Applied in Biomaterials Studies

      Abbreviations

      3.309.1. Introduction

      3.309.2. Transport Phenomena: Diffusive, Convective, and Reactive Transport Mechanisms

      3.309.3. Analysis of Transport Models in Porous Media

      3.309.4. Conclusion

      3.310. Computational Methods Related to Reaction Chemistry

      Abbreviations

      Acknowledgments

      3.310.1. Introduction

      3.310.2. Computational Methods

      3.310.3. Applications

      3.311. Molecular Simulation Methods to Investigate Protein Adsorption Behavior at the Atomic Level

      Abbreviations

      Acknowledgments

      3.311.1. Introduction

      3.311.2. Fundamental Aspects of Protein Adsorption Behavior

      3.311.3. Molecular Simulation Methods and Their Relevance to Protein Adsorption

      3.311.4. Application of All-Atom Modeling Methods to Simulate Protein–Surface Interactions

      3.311.5. Current Limitations and Directions for Further Development

      3.311.6. Concluding Remarks

      3.312. Cell Culture Systems for Studying Biomaterial Interactions with Biological Barriers

      Abbreviations

      Acknowledgments

      3.312.1. Introduction

      3.312.2. The Upper Respiratory Tract: Barrier Functions of the Bronchial Epithelium

      3.312.3. The Lower Respiratory Tract: Cell Culture Models Mimicking the Biological Barriers of the Distal Lung

      3.312.4. In Vitro Studies with Endothelial Cells from the BBB

      3.312.5. Conclusion and Future Perspectives

      3.313. Histological Analysis

      Abbreviations

      3.313.1. Introduction

      3.313.2. Preservation of Tissue

      3.313.3. Undecalcified Versus Decalcified

      3.313.4. Embedding Techniques

      3.313.5. Sectioning Techniques

      3.313.6. Staining Methods

      3.313.7. Quantification Methods

      3.313.8. Summary and Future Directions

      3.314. Materials to Control and Measure Cell Function

      Abbreviations

      3.314.1. Introduction

      3.314.2. Influence of Surface Features on Cell Function

      3.314.3. Influence of Surface Features on Bacteria Function

      3.314.4. Applications in BioMEMs/Microsystems Fields

      3.314.5. Conclusions

      3.315. Biological Microelectromechanical Systems (BioMEMS) Devices

      Abbreviations

      Acknowledgments

      3.315.1. Introduction

      3.315.2. Cell Adhesions to the Microenvironment

      3.315.3. BioMEMS Devices to Measure Traction Forces

      3.315.4. BioMEMS Devices to Apply Forces to Cells

      3.315.5. Microfluidic Systems

      3.315.6. Future Directions

      3.316. Immunohistochemistry

      Abbreviations

      3.316.1. Introduction to Immunohistochemistry

      3.316.2. Factors Contributing to Antibody–Antigen Interaction

      3.316.3. Visualization of Antibody by Enzymatic or Fluorescent Labeling and The Advantages and Disadvantages

      3.316.4. Basic Immunohistochemistry Protocols and Their Advantages and Disadvantages for Biomaterial Science

      3.316.5. Detection of Pathobiological Processes and Associated Cellular Events in an Implanted Site

      3.316.6. Implant Evaluation Using Immunohistochemical Methods

      3.317. Fluorescence Imaging of Cell–Biomaterial Interactions

      Abbreviations

      Acknowledgments

      3.317.1. Introduction

      3.317.2. Principles, Instrumentation, and Methodology for Cell Imaging

      3.317.3. Probing Cell–Biomaterial Interactions

      3.317.4. Looking to the Future

      3.318. Molecular Imaging

      Abbreviations

      3.318.1. Introduction

      3.318.2. Nanomaterials

      3.318.3. Nanovesicles

      3.318.4. Polymeric Assemblies

      3.318.5. Future Outlook

      3.319. Characterization of Nanoparticles in Biological Environments

      Abbreviations

      Acknowledgments

      3.319.1. Introduction

      3.319.2. Interactions of Nanoparticles

      3.319.3. Characterization of Nanoparticles in or from Solution

      3.319.4. Examples of Nanoparticles in Biological Environments

      3.319.5. Conclusions and Outlook

      3.320. Nanostructured Polymeric Films for Cell Biology

      Abbreviations

      3.320.1. Introduction

      3.320.2. Controlled Protein Adsorption on BCP and Polymer Blend Surfaces

      3.320.3. Protein and Cell Binding via Affinity Interactions Templated by Polymer Surfaces

      3.320.4. Coassembly of BCPS with Peptides and Proteins in Thin Films

      3.320.5. BCP Surfaces for Biocompatibility and Antifouling Applications

      3.320.6. BCP Micelle Surfaces for Controlled Release Applications

      3.320.7. Conclusion

      3.321. Microarrays in Biomaterials Research

      Abbreviations

      3.321.1. Introduction

      3.321.2. Principle of Microarray

      3.321.3. Application of Microarray

      3.321.4. Future Prospects of Microarray

      3.322. Infrared and Raman Microscopy and Imaging of Biomaterials

      Abbreviations

      3.322.1. Introduction

      3.322.2. Instrumentation, Sampling, and Data Processing

      3.322.3. Applications to Biomaterials

      3.322.4. Conclusions

      3.323. Magnetic Resonance of Bone Microstructure and Chemistry

      Abbreviations

      3.323.1. Introduction

      3.323.2. Fundamentals of Magnetic Resonance

      3.323.3. Quantitative MRI of Trabecular and Cortical Bone Microstructure

      3.323.4. Bone Water and Porosity

      3.323.5. NMR Spectroscopy and MRI of Bone Matrix and Mineral

      3.323.6. Summary and Conclusions

      3.324. Fluorescent Nanoparticles for Biological Imaging

      Acknowledgments

      3.324.1. Introduction

      3.324.2. Fluorescent Nanoparticles: Synthesis and Surface Modification

      3.324.3. Fluorescent Nanoparticles: In Vitro Applications

      3.324.4. Fluorescent Nanoparticles: In Vivo Applications

      3.324.5. Future Perspective

      3.325. Imaging Mineralized Tissues in Vertebrates

      Abbreviations

      3.325.1. Introduction

      3.325.2. Structure of Mineralized Tissues

      3.325.3. Heterogeneity of Mineral Content and the Need for Imaging Techniques

      3.325.4. Estimates of Total Bone Mineral Content

      3.325.5. Imaging of Mineralized Tissues

      3.325.6. Property Mapping in Mineralized Tissues

      3.325.7. Conclusions

      3.326. Imaging and Diagnosis of Biological Markers

      Abbreviations

      3.326.1. Introduction

      3.326.2. Principles of MR and the Implications for Imaging and Diagnosis

      3.326.3. Viable Molecules, Nuclei, and Experiments for MR Studies

      3.326.4. Case Study: Biological Markers for the Diagnosis of DDD

      3.326.5. Case Study: MR for Diagnosing Bone Disease and Treatment

      3.326.6. Summary and Future of Imaging and Diagnosis of Biological Markers

      3.327. Intracellular Probes

      Abbreviations

      3.327.1. Introduction

      3.327.2. Fluorescence-Based Intracellular Probes

      3.327.3. Optical-Label-Free Intracellular Probes

      3.327.4. Conclusion

      3.328. Biosensors Based on Sol–Gel-Derived Materials

      Abbreviations

      3.328.1. Introduction

      3.328.2. Sol–Gel Bioencapsulation

      3.328.3. Applications of Sol–Gel Biosensors

      3.328.4. Conclusions and Future Trends

      3.329. Hydrogels in Biosensing Applications

      3.329.1. Introduction

      3.329.2. Physicochemical Sensing Mechanisms

      3.329.3. Biochemical Sensing Mechanisms

      3.329.4. Summary

      3.330. Carbon Nanotube-Based Sensors: Overview

      3.330.1. Introduction

      3.330.2. CNTs and Related Carbon-Based Nanostructures

      3.330.3. Manufacturing Devices from Carbon Nanostructures

      3.330.4. Sensing Applications of Carbon Nanostructures

      3.330.5. Future Opportunities

      3.331. Conjugated Polymers for Biosensor Devices

      Abbreviations

      3.331.1. Conjugated Polymers (CPs): History and Perspectives

      3.331.2. Using CPs for Electrochemical Biosensor Devices

      3.331.3. Using CPs for Optical Biosensor Devices

      4.401. The Concept of Biocompatibility

      Acknowledgment

      4.401.1. Introduction

      4.401.2. Wound-Healing Responses Underlying Biocompatibility

      4.401.3. Characteristic Features of Tissue Around Implants: Emerging Insights

      4.401.4. Summary and Considerations for the Future

      4.402. Biocompatibility and the Relationship to Standards: Meaning and Scope of Biomaterials Testing

      Abbreviations

      4.402.1. Introduction

      4.402.2. Biocompatibility

      4.402.3. Materials for Medical Devices

      4.402.4. In Vitro Tests for Biocompatibility

      4.402.5. In Vivo Tests for Biocompatibility

      4.402.6. Inflammation, Wound Healing, and the Foreign-Body Response

      4.402.7. Hemocompatibility

      4.402.8. Immune Responses

      4.402.9. Summary and Conclusion

      4.403. The Innate Response to Biomaterials

      Abbreviations

      4.403.1. Introduction

      4.403.2. Biomaterial Changes

      4.403.3. Inflammation and Biomaterials

      4.403.4. Evasion Innate Immune System Activation

      4.403.5. Enhancement of Innate Immune System Activation

      4.403.6. Concluding Remarks

      4.404. Adaptive Immune Responses to Biomaterials

      4.404.1. Introduction

      4.404.2. Recognition of Biomaterials by the Adaptive Immune System

      4.404.3. Consequences of the Adaptive Response

      4.404.4. Approaches to Engineer Adaptive Responses with Biomaterials

      4.404.5. Conclusions

      4.405. Leukocyte–Biomaterial Interaction In Vitro

      Abbreviations

      4.405.1. Introduction

      4.405.2. Characterizing the Inflammatory Response

      4.406. Protein Interactions with Biomaterials

      4.406.1. Introduction

      4.406.2. Surface Wettability, Topography, and Protein Adsorption

      4.406.3. Surface-Activated Coagulation

      4.406.4. Immune Complement at Biomaterials

      4.406.5. Consequences of Protein Adsorption

      4.406.6. Summary and Future Directions

      4.407. Bacterial Adhesion and Biomaterial Surfaces

      Abbreviations

      4.407.1. Introduction

      4.407.2. Laboratory Methods for the Study of Bacterial Adhesion

      4.407.3. Bacterial Characterization Methods

      4.407.4. Theory and Mechanisms of Bacterial Adhesion

      4.407.5. Mechanisms of Bacterial Adhesion

      4.407.6. The Influence of Biomaterial Surface Properties on Bacterial Adhesion

      4.407.7. Strategies to Reduce Bacterial Adhesion

      4.407.8. Summary and Perspectives

      4.408. Integrin-Activated Reactions to Metallic Implant Surfaces

      Abbreviations

      4.408.1. Introduction

      4.408.2. Integrins

      4.408.3. Integrin Function

      4.408.4. Integrin-Signaling Pathways

      4.408.5. Integrin Binding to Biomaterials

      4.408.6. Functionalizing Implant Surfaces Using Adhesion Molecules

      4.408.7. Conclusions

      4.409. Surfaces and Cell Behavior

      Abbreviations

      Acknowledgments

      4.409.1. Introduction

      4.409.2. Manufacturing Surface Topography

      4.409.3. History of Differentiated Cell Guidance by Nanostructures

      4.409.4. The History of Stem Cells and Nanotopography

      4.409.5. Low Adhesion Materials

      4.409.6. Nanotopography as a Noninvasive Tool for Cell Biology

      4.409.7. Conclusions and Future Perspectives

      4.410. Sterilization of Biomaterials of Synthetic and Biological Origin

      Abbreviations

      4.410.1. Introduction

      4.410.2. Sterilization Methods

      4.410.3. Sterilization of Biomaterials of Synthetic and Biological Origin

      4.410.4. Evaluation of Effect of Sterilization on Biomaterials

      4.411. Peptide- and Protein-Modified Surfaces

      Amino Acid Abbreviations

      Acknowledgments

      4.411.1. Introduction

      4.411.2. Peptides Versus Proteins

      4.411.3. Immobilization Strategies

      4.411.4. Functional Parameters

      4.411.5. Sample Applications

      4.411.6. Conclusions and Outlook

      4.412. Rational and Combinatorial Methods to Create Designer Protein Interfaces

      Abbreviations

      4.412.1. Introduction

      4.412.2. Rational Engineering

      4.412.3. Combinatorial Engineering

      4.412.4. Protein Engineering Considerations for Biomaterials: The Interface Between Proteins and Materials

      4.412.5. Conclusions and Future Directions

      4.413. Patterned Biointerfaces

      Abbreviations

      Acknowledgments

      4.413.1. Introduction

      4.413.2. Patterning Techniques

      4.413.3. Biointerfacing with Patterned Surfaces

      4.414. Molecular Biomimetic Designs for Controlling Surface Interactions

      Abbreviations

      Acknowledgments

      4.414.1. Introduction

      4.414.2. Biomaterials' Failure Mechanisms

      4.414.3. Approaches for Controlling Surface Biological Interactions

      4.414.4. ECM Biomimetics

      4.414.5. Summary and Outlook

      4.415. Surface Engineering Using Peptide Amphiphiles

      Abbreviations

      Acknowledgments

      4.415.1. Introduction

      4.415.2. The Amphiphilic Nature of Life's Events

      4.415.3. PAs: Synthesis, Physicochemical Characterization, and Self-Assembly

      4.415.4. The Multifunctional (Soft) Nanoparticle Concept

      4.415.5. Protein-Like Structures to 3D Hierarchical Nanostructures

      4.415.6. Applications in Biomedical Sciences: Tissue and Stem Cell Engineering

      4.415.7. Summary and Future Directions

      4.417. Tethered Antibiotics

      Abbreviations

      Acknowledgments

      4.417.1. Implant-Associated Infection in Orthopedic Materials

      4.417.2. Bacterial Responses to Orthopedic Implants

      4.417.3. Antibiotic Prophylaxis and Treatment of Surgical Infection

      4.417.4. Surface Tethering of Antibiotics to Prevent Bacterial Adhesion

      4.418. Engineering Interfaces for Infection Immunity

      Abbreviations

      4.418.1. The Problem

      4.418.2. Innate and Adaptive Immune Responses

      4.418.3. Engineering Infection Immunity

      4.418.4. Concluding Remarks

      4.419. Vaccine and Immunotherapy Delivery

      Abbreviations

      Acknowledgment

      4.419.1. Introduction

      4.419.2. The Paradigm of Immune Responses in Infection Versus Vaccination

      4.419.3. Biomaterials as Delivery Vehicles for Vaccines and Immunomodulators

      4.419.4. Biomaterials as Immunostimulators and Carriers of Immunostimulatory Adjuvants for Vaccines

      4.419.5. Future Directions

      4.419.6. Conclusions

      4.420. Drug Delivery via Heparin Conjugates

      Abbreviations

      4.420.1. Rationale for Using Heparin Conjugates for Drug Delivery

      4.420.2. Methods for Heparin Immobilization

      4.420.3. Use of Heparin Mimetic Molecules for Delivery of Heparin-Binding Growth Factors

      4.420.4. Summary

      4.421. Self-Assembled Prodrugs

      Abbreviations

      Acknowledgments

      4.421.1. Introduction

      4.421.2. Challenges and Opportunities of Hydrogels in Drug Delivery

      4.421.3. Self-Assembled Prodrugs

      4.421.4. Self-Assembled Irreversible Prodrug-Based Hydrogels

      4.421.5. Conclusions and Outlook

      4.422. pH-Responsive Polymers for the Intracellular Delivery of Biomolecular Drugs

      4.422.1. Introduction

      4.422.2. Acid–Base Equilibria and pH-Responsive Chemistries

      4.422.3. Anionic pH-Responsive Polymers

      4.422.4. Acid-Degradable Delivery Vehicles

      4.422.5. Osmotically Disruptive Cationic Polymers

      4.422.6. Histidine- and Imidazole-Containing Copolymers

      4.422.7. Fusogenic Peptides

      4.422.8. Future Perspectives

      4.423. Polymeric Drug Conjugates by Controlled Radical Polymerization

      Abbreviations

      Acknowledgments

      4.423.1. Introduction

      4.423.2. Overview of Controlled Radical Polymerization

      4.423.3. Examples of Polymer Conjugates Synthesized by Controlled Radical Polymerization

      4.423.4. Prospects and Challenges

      4.424. Nanoparticles for Nucleic Acid Delivery

      Abbreviations

      Acknowledgments

      4.424.1. Introduction

      4.424.2. General Classes of Nucleic Acid Delivery Systems

      4.424.3. Classes of Nonviral Vectors

      4.424.4. Opportunities and Challenges in NP Therapeutics: Biological Barriers to Nucleic Acid Delivery

      4.424.5. Conclusions

      4.426. Electrospun Fibers for Drug Delivery

      Abbreviations

      4.426.1. Introduction

      4.426.2. Principles of Electrospinning

      4.426.3. Drug Delivery from Electrospun Fibers

      4.426.4. Conclusions and Future Directions

      4.427. Cell-Demanded Release of Growth Factors

      Abbreviations

      Acknowledgments

      4.427.1. Introduction

      4.427.2. Enabling Polymer Hydrogels for Cell-Demanded Release

      4.427.3. Preclinical Evaluation in Angiogenesis

      4.427.4. Conclusion and Future Directions

      4.428. Sol–Gel Processed Oxide Controlled Release Materials

      Abbreviations

      4.428.1. Introduction

      4.428.2. Sol–Gel Process

      4.428.3. Drug Release Mechanisms

      4.428.4. Control of Release Kinetics

      4.428.5. Biocompatibility and Resorption

      4.428.6. Applications

      4.428.7. Summary

      4.429. Ordered Mesoporous Silica Materials

      Abbreviations

      4.429.1. Introduction

      4.429.2. Ordered Mesoporous Materials: General Remarks

      4.429.3. Biocompatibility of Mesoporous Materials

      4.429.4. Mesoporous Materials for Local Drug Delivery

      4.429.5. Bioactivity of Mesoporous Matrices

      4.429.6. Hierarchical Macroporous Scaffolds for Bone Tissue Engineering

      4.430. Silica-Based Mesoporous Nanospheres

      Abbreviations

      4.430.1. Introduction

      4.430.2. Synthesis of Nonporous Silica Nanospheres

      4.430.3. Synthesis of MSNs

      4.430.4. Physicochemical Properties and Characterization

      4.430.5. Unique Biomaterial Considerations

      4.430.6. Conclusion

      4.431. Encapsulation of Cells (Cellular Delivery) Using Sol–Gel Systems

      Abbreviations

      Acknowledgments

      4.431.1. Introduction

      4.431.2. Sol–Gel Silicates

      4.431.3. Cell Delivery in Temperature-Sensitive Sol–Gel Systems

      4.431.4. Conclusion and Future Directions

      4.432. Layered Double Hydroxides as Controlled Release Materials

      Abbreviations

      4.432.1. Introduction

      4.432.2. LDHs and Intercalation

      4.432.3. Stabilization of Biomolecules via Intercalation

      4.432.4. Controlled Release of Intercalated Biomolecules

      4.432.5. Enhanced Cellular Uptake

      4.432.6. Conclusion and Perspectives

      4.433. Porous Metal–Organic Frameworks as New Drug Carriers

      Abbreviations

      Acknowledgements

      4.433.1. Introduction

      4.433.2. Adsorption and Delivery of Therapeutic Molecules

      4.433.3. Adsorption and Delivery of Biological Gases

      4.433.4. Toxicity and Stability Issues

      4.433.5. Formulation

      4.433.6. Conclusion and Perspectives

      4.434. Hybrid Magnetic Nanoparticles for Targeted Delivery

      4.434.1. Introduction

      4.434.2. Magnetism of MNPs

      4.434.3. MF Design and Preparation

      4.434.4. Size/Surface Requirements with Regard to i.v. Administration

      4.434.5. MNPs as Contrast Agents for MRI

      4.434.6. MNPs as Mediators for Magnetic Hyperthermia

      4.434.7. MNPs Within Carriers for Drug Delivery

      4.434.8. Conclusion

      5.501. Scaffolds: Flow Perfusion Bioreactor Design

      Abbreviations

      Acknowledgments

      5.501.1. Introduction

      5.501.2. Mass Transport within Scaffolds

      5.501.3. Perfusion Bioreactors

      5.501.4. Design Parameters of Flow Perfusion Bioreactors

      5.501.5. Current Flow Perfusion Bioreactor Designs and Functions

      5.501.6. Future Progress

      5.501.7. Conclusions

      5.502. Engineering Scaffold Mechanical and Mass Transport Properties

      Abbreviations

      Acknowledgments

      5.502.1. Introduction

      5.502.2. Hierarchical Computational Scaffold Design

      5.502.3. Fabricating Designed Scaffolds

      5.502.4. Designed Scaffold Architecture Influences Tissue Regeneration

      5.502.5. Conclusion

      5.503. Biomaterials and the Microvasculature

      Abbreviations

      Acknowledgment

      5.503.1. Introduction

      5.503.2. Biomedical Engineering Applications Dependent on Neovascularization In or Around Biomaterials

      5.503.3. Survey of Neovascularization

      5.503.4. Properties of Biomaterials Regulating Microvascular Network Formation In, On, and Around Biomaterials

      5.503.5. Case Studies

      5.504. Effect of Substrate Modulus on Cell Function and Differentiation

      Abbreviations

      5.504.1. Introduction

      5.504.2. Young's Modulus

      5.504.3. Fabrication of Substrates with Defined Material Modulus

      5.504.4. Cell Functions and Differentiation

      5.504.5. Conclusion

      5.505. Quantifying Integrin–Ligand Engagement and Cell Phenotype in 3D Scaffolds

      Abbreviations

      5.505.1. Introduction

      5.505.2. Quantifying Integrin–Ligand Forces

      5.505.3. Quantifying Type and Number of Integrin–Ligand Binding

      5.505.4. Conclusion

      5.506. Effects of Mechanical Stress on Cells

      Abbreviations

      5.506.1. Introduction

      5.506.2. Mechanical Environment of the Cell

      5.506.3. Subcellular Structures Involved in Mechanotransduction

      5.506.4. Molecular Mechanotransduction

      5.506.5. Response of Cells to Mechanical Stress and Implications for Tissue Engineering

      5.507. Tissue Engineering and Selection of Cells

      Abbreviations

      Acknowledgment

      5.507.1. Why Do Tissue Engineering Approaches Need a Cell Source?

      5.507.2. Cell Sources Used in Tissue Engineering Strategies

      5.507.3. Patient Delivery Challenges: Controlling Cells in the Body

      5.507.4. Donor Versus Host Immune Issues

      5.507.5. Donor Versus Host: Cell/Tissue Integration

      5.507.6. Safety and Stability

      5.507.7. Conclusion

      5.508. Scaffold Materials for hES Cell Culture and Differentiation

      Abbreviations

      5.508.1. Introduction

      5.508.2. Biomaterials for Undifferentiated hESC Culture

      5.508.3. Biomaterials for hESC Differentiation

      5.508.4. Conclusions and Future Work

      5.508.5. Summary

      5.509. Cell Encapsulation

      Abbreviations

      5.509.1. Introduction

      5.509.2. Methods

      5.509.3. Process

      5.509.4. Representative Applications

      5.509.5. Summary

      5.510. Engineered Bioactive Molecules

      Abbreviations

      Acknowledgments

      5.510.1. Introduction

      5.510.2. Proteins

      5.510.3. Nucleic Acids

      5.510.4. Lipids and Liposomes

      5.511. Rotating-Wall Vessels for Cell Culture

      Abbreviations

      5.511.1. Introduction

      5.511.2. Operating Principles of RWV

      5.511.3. Scaffolds and Microcarriers for Cell Culture in RWV

      5.511.4. Cell Culture in RWV

      5.511.5. Other Applications of RWV

      5.512. In Vivo Bioreactors

      Abbreviations

      5.512.1. Introduction

      5.512.2. Elements of the In Vivo Bioreactor

      5.512.3. Applications and Tissues

      5.513. Systems Biology in Biomaterials and Tissue Engineering

      Abbreviations

      5.513.1. Introduction

      5.513.2. Discrete Component-Centered Approach

      5.513.3. High-Throughput Component-Centered Approach

      5.513.4. Process-Centered Systems Approach

      5.513.5. Future Outlook

      5.514. Chondrocyte Transplantation and Selection

      Abbreviations

      5.514.1. Introduction

      5.514.2. Cell Therapy and Cartilage Regeneration: State of the Art

      5.514.3. Cell Therapy Concepts in Cartilage Disease and Osteoarthritis

      5.514.4. Molecular Control Mechanisms in the Knee Joint – Implications for Cartilage Repair and OA

      5.514.5. The Uniqueness of Hyaline Cartilage Chondrocytes

      5.514.6. Adult Stem Cells and Stem Cell Niches

      5.514.7. Improvements in ACT Cell Technology – Alternative Cell Sources

      5.514.8. Autologous Use of Cells

      5.514.9. Universal Donor Cell Lines for Cartilage Repair

      5.514.10. Conclusion

      5.515. Cartilage Tissue Engineering

      Abbreviations

      5.515.1. Introduction

      5.515.2. Articular Cartilage Maturation and Synovial Fluid Formation

      5.515.3. Mechanical Properties and Models of Articular Cartilage and Synovial Fluid

      5.515.4. Mechanical Effects on Cartilage Maturation and Synovial Fluid Pathology

      5.515.5. Engineering Cartilaginous Tissue and Synovial Fluid

      5.516. Biomaterials in Cartilage Tissue Engineering

      Abbreviations

      5.516.1. Introduction

      5.516.2. Cell Sources

      5.516.3. Scaffolds

      5.516.4. Growth Factors

      5.516.5. Clinical Repair Techniques

      5.516.6. Conclusion

      5.517. Tissue Engineering of the Temporomandibular Joint

      Abbreviations

      5.517.1. Introduction

      5.517.2. Gross Anatomy and Physiology of the TMJ

      5.517.3. Characterization of TMJ Tissues

      5.517.4. Pathology of the TMJ

      5.517.5. Current Therapies

      5.517.6. Tissue Engineering

      5.517.7. Future Directions for TMJ Tissue Engineering

      5.517.8. Conclusions

      5.518. Endocultivation: Computer Designed, Autologous, Vascularized Bone Grafts

      5.518.1. Introduction

      5.518.2. Endocultivation of Autologous Vascularized Bone Grafts

      5.518.3. Clinical Applications of Endocultivation: Tissue Engineering of Autologous Customized Vascularized Bone Replacements In Vivo

      5.518.4. Clinical Results

      5.518.5. Future Improvements

      5.518.6. Summary

      5.519. Biomaterials Selection for Dental Pulp Regeneration

      Abbreviations

      5.519.1. Introduction

      5.519.2. Biomaterial Selections

      5.519.3. In Vivo Dental Pulp Regeneration: State of the Art

      5.519.4. Conclusions

      5.520. Bioactive Ceramics and Bioactive Ceramic Composite-Based Scaffolds

      Abbreviations

      5.520.1. Introduction

      5.520.2. Scaffold Requirements

      5.520.3. Fundamentals of Ceramic Bioactivity

      5.520.4. Characteristics of Bioactive Ceramics and Bioactive Ceramic Composite-Based Scaffolds for Bone Tissue-Engineering Scaffold

      5.520.5. Modifications of Bioactive Ceramics and Bioactive Ceramic Composite-Based Scaffolds

      5.520.6. Conclusion and Future Directions

      5.521. Calcium Phosphates and Bone Induction

      Abbreviations

      5.521.1. Bone and Its Biology

      5.521.2. Bone Grafting and the Strategies

      5.521.3. Biomaterials for Bone Substitution

      5.521.4. Bone Induction Associated with Materials

      5.521.5. Role of Calcium Phosphate in Bone Induction

      5.521.6. Material Factors

      5.521.7. Mechanism of Bone Induction

      5.521.8. Clinical Significance of Osteoinductive Materials

      5.521.9. Future Directions

      5.522. Bone Tissue Engineering: Growth Factors and Cytokines

      Abbreviations

      5.522.1. Bone Biology

      5.522.2. Growth Factors, Cytokines, Nomenclature, Mechanism of Action

      5.522.3. Bone Tissue Engineering: Growth Factors and Cytokines

      5.522.4. Cytokines and Bone

      5.522.5. Translational Applications of Growth Factors and Cytokines in Bone Tissue Engineering

      5.523. Carbon Nanotubes: Applications for In Situ Implant Sensors

      Abbreviations

      Acknowledgments

      5.523.1. Introduction

      5.523.2. Making Orthopedic Implant Sensors

      5.523.3. Biological Responses to Orthopedic Implant Sensors

      5.523.4. Sensing Ability of Orthopedic Implant Sensors

      5.523.5. Discussion

      5.523.6. Conclusions

      5.524. Biomaterials for Replacement and Repair of the Meniscus and Annulus Fibrosus

      Abbreviations

      Acknowledgments

      5.524.1. Overview

      5.524.2. Introduction

      5.524.3. Structure and Function of the Knee Meniscus

      5.524.4. Structure and Function of the AF

      5.524.5. Current Clinical Treatments for Damage to or Degeneration of the Meniscus and AF

      5.524.6. Current Products for Meniscus and AF Repair and Replacement

      5.524.7. Emerging Products for Meniscus and AF Repair and Replacement: Tissue Engineering

      5.524.8. Engineering Fiber-Reinforced Tissues with Nanofibrous Scaffolds

      5.524.9. Preclinical Models and Evaluation Tools for Engineered AF and Meniscus Products

      5.524.10. Conclusions and Future Directions

      5.525. Tissue Engineering Approaches to Regeneration of Anterior Cruciate Ligament

      Abbreviations

      Acknowledgments

      5.525.1. Introduction

      5.525.2. Biomaterials for Ligament Tissue Engineering

      5.525.3. Scaffold Design

      5.525.4. Cell Source

      5.525.5. Bioreactor System

      5.525.6. Local Delivery of Growth Factors

      5.525.7. Animal Models for ACL Regeneration

      5.525.8. Ligament–Bone Interface

      5.525.9. Summary

      5.526. Tissue Engineering of Muscle Tissue

      5.526.1. Introduction

      5.526.2. Importance of Skeletal Muscle Tissue Engineering

      5.526.3. Muscle Development and Repair

      5.526.4. Scaffolding Materials

      5.526.5. Additions to Current Matrices

      5.526.6. Vascularization

      5.526.7. Innervation

      5.526.8. Alternative Cell Types for Skeletal Muscle Engineering

      5.526.9. Electrical and Mechanical Stimulation of Skeletal Muscle

      5.526.10. Matrix Metalloproteinases

      5.526.11. Immune Response to Engineered Muscle

      5.526.12. The Aged Niche

      5.526.13. Pathological Environment

      5.526.14. Future Directions

      5.527. Cardiovascular Tissue Engineering

      Abbreviations

      5.527.1. Introduction

      5.527.2. Cardiac Patches

      5.527.3. Cell Delivery Using Biomaterials

      5.527.4. Tissue Engineering of Artificial Vesseles

      5.527.5. Tissue Engineering of Heart Valves

      5.528. Tissue Engineering of Heart Valves

      5.528.1. The Ideal Valvular Substitute

      5.528.2. Strategies in Autologous Heart Valve Tissue Engineering

      5.528.3. In Vitro Heart Valve Tissue Engineering

      5.528.4. In Vivo Heart Valve Tissue Engineering

      5.528.5. Cell Sources for Heart Valve Tissue Engineering

      5.528.6. Toward Clinical Application – Outlook for the Future

      5.529. Biomaterials for Cardiac Cell Transplantation

      Abbreviations

      5.529.1. Introduction

      5.529.2. Biomaterial Design Requirements for Cardiac Cell Transplantation

      5.529.3. Current Materials

      5.529.4. Concluding Remarks

      5.530. Medical Applications of Cell Sheet Engineering

      Abbreviations

      Acknowledgments

      5.530.1. Introduction

      5.530.2. Functional Tissue Engineering with Cell Sheets

      5.530.3. Clinical Application of Cell Sheet Tissue Engineering

      5.530.4. Conclusions

      5.531. Peripheral Nerve Regeneration

      Abbreviations

      5.531.1. Introduction

      5.531.2. Current Approaches to Bridging Nerve Gaps

      5.531.3. Concluding Statements

      5.532. Nerve Tissue Engineering

      Abbreviations

      5.532.1. Introduction

      5.532.2. State of the Art of PNS Tissue Engineering

      5.532.3. State of the Art of CNS Tissue Engineering (see Chapter 5.533, Biomaterials for Central Nervous System Regeneration and Chapter 6.630, Biomaterials for Spinal Cord Repair)

      5.532.4. Concluding Remarks

      5.533. Biomaterials for Central Nervous System Regeneration

      5.533.1. Introduction

      5.533.2. Biomaterial Therapy Options

      5.533.3. Spinal Cord Injury

      5.533.4. Alzheimer's Disease

      5.533.5. Parkinson's

      5.533.6. Biomaterials Used with Stem Cell Therapy

      5.533.7. Summary of Biomaterial Therapies in CNS Injury/Disease

      5.535. Cartilage Regeneration in Reconstructive Surgery

      Abbreviations

      5.535.1. Introduction

      5.535.2. Role of Tissue Engineering

      5.535.3. Cell Sources and Materials

      5.535.4. Characterization of Scaffolds In Vitro and In Vivo

      5.535.5. Conclusions

      5.536. Tissue-Engineering Hollow Noncardiac Intrathoracic Organs: State-of-the-Art 2010

      Abbreviations

      5.536.1. Introduction

      5.536.2. Historical Background

      5.536.3. Tissue-Engineered Trachea: Basic Sciences to Clinical Application and Transplantation

      5.536.4. Tissue-Engineered Larynx for Total Laryngeal Replacement and Transplantation: The Ultimate Goal

      5.536.5. Future Challenges and Goals

      5.536.6. Conclusions

      5.537. Adipose Tissue Engineering

      Abbreviations

      5.537.1. Introduction

      5.537.2. Adipose Tissue Engineering

      5.537.3. Adipose Tissue Structure and Function

      5.537.4. Biomaterials for Adipose Tissue Engineering

      5.537.5. Future Outlook

      5.538. Finger

      Abbreviations

      5.538.1. Introduction

      5.538.2. Periosteum for Human Phalanx Model

      5.538.3. In Vivo Model for Phalanx

      5.538.4. Development of the Human Phalanx Model

      5.538.5. Assessment of the Human Phalanx Model

      5.538.6. Conclusion and Future Directions

      5.539. From Tissue to Organ Engineering

      Abbreviations

      Acknowledgment

      5.539.1. Introduction

      5.539.2. Biomaterials

      5.539.3. Cells for Use in Tissue Engineering

      5.539.4. Cell Therapy with Injectable Substances

      5.539.5. Tissue Engineering of Specific Structures

      5.539.6. Summary and Conclusion

      5.540. Kidney Tissue Engineering

      Acknowledgment

      5.540.1. Introduction

      5.540.2. Developmental Techniques

      5.540.3. Renal Progenitor Cells

      5.540.4. Cellular-Based Therapies

      5.540.5. Stem Cells for Use in Renal Tissue Regeneration

      5.540.6. In Situ Kidney Development

      5.540.7. Renal Tubular Assist Devices

      5.540.8. Summary and Conclusions

      5.541. Liver Tissue Engineering

      Abbreviations

      5.541.1. Introduction

      5.541.2. Extracorporeal Liver Support Devices

      5.541.3. Implantable Hepatic Support Systems

      5.541.4. Conclusions and Future Directions

      5.542. Organ Printing

      Abbreviations

      5.542.1. Introduction

      5.542.2. 2D Patterning and Cell Printing

      5.542.3. 3D Organ-Printing Processes

      5.542.4. Future Directions

      5.542.5. Conclusions

      6.601. Current and Projected Utilization of Total Joint Replacements

      Abbreviations

      6.601.1. Introduction

      6.601.2. International Total Hip and Knee Implant Registries

      6.601.3. Public Data Sources for Orthopedic Implant Utilization in the United States

      6.601.4. Current Utilization of Total Joint Replacements

      6.601.5. Projected Utilization of Total Joint Replacements

      6.601.6. Summary

      6.602. Bone Cement

      Abbreviations

      6.602.1. Introduction

      6.602.2. Bone Cement Chemistry

      6.602.3. Bone Cement Applications

      6.602.4. Mechanical Properties of PMMA–Bone Cement

      6.602.5. Improving PMMA–Bone Cement

      6.602.6. Summary and Concluding Remarks

      6.603. Ultrahigh Molecular Weight Polyethylene Total Joint Implants*

      Abbreviations

      6.603.1. Introduction

      6.603.2. General Properties and Processing of UHMWPE

      6.603.3. The Effects of Sterilization and Early Developments

      6.603.4. Cross-linking Technologies

      6.603.5. Vitamin E-Stabilized, Radiation Cross-linked UHMWPE

      6.603.6. Other UHMWPEs with Clinical Potential

      6.603.7. Conclusions and Future Directions

      6.604. Ceramic Prostheses: Clinical Results Worldwide

      Abbreviations

      6.604.1. Introduction

      6.604.2. History

      6.604.3. Early Clinical Results

      6.604.4. Evolution of the Mechanical Properties of Alumina and the New Alumina Matrix Composite

      6.604.5. Proven Long-Term Clinical Stability

      6.604.6. Biocompatibility

      6.604.7. Current Manufacturing State of the Art

      6.604.8. Ceramic Component Failure

      6.604.9. Recent Clinical Reports of the Use of the Latest Generation of Alumina Ceramics

      6.604.10. Statistical Observations of the Largest Ceramic Manufacturer Clinical Report Database (January 2000 to September 2009)

      6.604.11. Ceramic Component Squeaking

      6.604.12. The Beneficial Wear Properties of Alumina Ceramics Outweigh the Risk of Fracture

      6.604.13. Clinical Use of Ceramics in the Global Community

      6.604.14. Ceramics Allow Large Diameter Wear Couple with Little Wear Debris

      6.604.15. Conclusions

      6.605. Porous Coatings in Orthopedics

      Abbreviations

      6.605.1. Introduction

      6.605.2. Materials Used for Porous Coatings

      6.605.3. Properties of Porous-Coated Implants

      6.605.4. Design and Characterization of Porous Materials

      6.605.5. Porous Coatings in Tissue Engineering

      6.605.6. Summary and Future Directions

      6.606. Biological Effects of Wear Debris from Joint Arthroplasties

      Abbreviations

      Acknowledgments

      6.606.1. Introduction

      6.606.2. Orthopedic Wear Debris

      6.606.3. Biologic Reactions of the Host to Wear Debris

      6.606.4. Other Factors Modulating the Biological Activity of Wear Particles

      6.606.5. New In Vivo Models and Development of Particle-Induced Osteolysis

      6.606.6. Therapeutic Strategies

      6.606.7. Conclusion

      6.607. Fretting Corrosion of Orthopedic Implants

      Abbreviations

      6.607.1. Introduction

      6.607.2. Experimental Methods: Implant Fretting Corrosion

      6.607.3. Implant Fretting and Biocompatibility

      6.607.4. Conclusions

      6.608. Implant Debris: Clinical Data and Relevance

      Abbreviations

      6.608.1. Introduction

      6.608.2. Implant Debris Types: Particles and Ions

      6.608.3. Local Tissue Effects of Wear and Corrosion

      6.608.4. Systemic Effects of Wear and Corrosion

      6.608.5. Conclusions

      6.609. Orthopedic Implant Use and Infection

      Abbreviations

      6.609.1. Orthopedic Implants

      6.609.2. Periprosthetic Infection

      6.609.3. The Diagnostic Dilemmas

      6.609.4. An Interjection on Orthopedic Trauma

      6.609.5. Classification Schemes for Implant Infection

      6.609.6. Management of Periprosthetic Infection

      6.609.7. The Future of Implant Design in Orthopedic Infection

      6.609.8. Nanomolecular Permanent Modification of Biomaterials

      6.609.9. Conclusions

      6.610. Trends in Materials for Spine Surgery

      Abbreviations

      6.610.1. Introduction

      6.610.2. Anatomy and Physiology of the Spine

      6.610.3. Spinal Fusion

      6.610.4. Total Disc Arthroplasty

      6.610.5. Annulus Repair

      6.610.6. Concluding Remarks

      6.611. Injectable Bone Cements for Spinal Column Augmentation: Materials for Kyphoplasty/Vertebroplasty

      Abbreviations

      6.611.1. Introduction

      6.611.2. History of Spinal Column Augmentation with Injectable Bone Cements and Currently Accepted Indications

      6.611.3. Overview of Frequently Used Injectable Bone Cements for Spinal Augmentation

      6.611.4. Clinical Results of Spinal Column Augmentation with Injectable Bone Cements

      6.611.5. Complications in Spinal Column Augmentation

      6.611.6. Future Directions and Conclusions

      6.612. Biomaterials for Intervertebral Disc Regeneration

      Abbreviations

      6.612.1. Overview of Intervertebral Repair: Current Strategies

      6.612.2. Repair of the NP

      6.612.3. Repair for the AF

      6.613. Nucleus Replacement

      Abbreviations

      6.613.1. Introduction

      6.613.2. Ageing and Disk Injury

      6.613.3. Treatment Options

      6.613.4. Nucleus Replacement

      6.613.5. Considerations for Evaluating Nucleus Replacements In Vitro and In Vivo

      6.613.6. Summary

      6.614. Wear: Total Intervertebral Disc Prostheses

      Abbreviations

      6.614.1. Introduction to Total Disc Prostheses

      6.614.2. Basic Anatomy and Biomechanics of the Spine

      6.614.3. TDR Surgery

      6.614.4. TDR Design

      6.614.5. Evidence of TDR Wear

      6.614.6. TDR Wear Simulation

      6.614.7. Wear of Metal–PE TDR

      6.614.8. Wear of Metal–Metal TDR

      6.614.9. Wear of Alternative Material TDR

      6.614.10. Biological Response to TDR Wear Debris

      6.614.11. Conclusions

      6.615. Intervertebral Disc

      Abbreviations

      6.615.1. Background

      6.615.2. IVD Structure and Function

      6.615.3. IVD Preservation, Repair, and Regeneration

      6.615.4. Future Challenges

      6.616. Materials in Fracture Fixation

      Abbreviations

      6.616.1. Fracture Healing

      6.616.2. Basic Requirements of Biomaterials for Fracture Fixation Device

      6.616.3. Devices Used in Fracture Fixation

      6.617. Bone Tissue Grafting and Tissue Engineering Concepts

      6.617.1. Introduction

      6.617.2. Historical Overview

      6.617.3. Polymeric Bone Graft Substitutes to Tissue Engineering

      6.617.4. Bone Tissue Engineering

      6.617.5. Animal Models for Assessing Effectiveness of Bone Tissue Engineering Strategies

      6.618. Materials in Tendon and Ligament Repair

      Abbreviations

      6.618.1. Introduction

      6.618.2. Basic Properties of Tendon and Ligament

      6.618.3. Augmentation of Scaffolds

      6.618.4. Animal Models in Tendon and Ligament Research

      6.618.5. Graft Materials

      6.618.6. Clinical Application

      6.618.7. Summary

      6.620. Dental Graft Materials

      Abbreviations

      Acknowledgments

      6.620.1. Introduction

      6.620.2. Categories of Dental Grafting Materials

      6.620.3. Requirements and Novel Developments for Dental Graft Materials

      6.620.4. Summary

      6.621. Biomaterials and Their Application in Craniomaxillofacial Surgery

      Abbreviations

      6.621.1. Introduction

      6.621.2. Biomaterials and Implants in Craniomaxillofacial Surgery

      6.621.3. Considerations and Future Applications

      6.622. The Effect of Substrate Microtopography on Osseointegration of Titanium Implants

      Abbreviations

      Acknowledgments

      6.622.1. Introduction

      6.622.2. In Vitro Studies

      6.622.3. Mechanisms Mediating the Microtopography Effect

      6.622.4. In Vivo Studies

      6.622.5. Summary

      6.623. Materials in Fixed Prosthodontics for Indirect Dental Restorations

      Abbreviations

      6.623.1. General Introduction

      6.623.2. Indirect Restorations

      6.624. Cardiac Patch with Cells: Biological or Synthetic

      Abbreviations

      6.624.1. Native Myocardium: Unique Tissue Properties

      6.624.2. Clinical Indications for Myocardial Patch Repair

      6.624.3. Patch Materials in Current Clinical Use

      6.624.4. Experimental Synthetic Polymers

      6.624.5. Strategies for Myocardial Tissue Engineering

      6.624.6. In Vivo Maturation of a Cardiac Patch

      6.624.7. Scientific Frontiers

      6.624.8. Clinical Relevance and Perspectives

      6.624.9. Summary

      6.625. Long-Term Implantable Ventricular Assist Devices (VADs) and Total Artificial Hearts (TAHs)

      Abbreviations

      Acknowledgments

      6.625.1. Introduction

      6.625.2. Configuration

      6.625.3. LVAD Evolution

      6.625.4. Partial Circulatory Support VADs

      6.625.5. Total Artificial Heart

      6.625.6. Conclusions

      6.626. Cardiac Valves: Biologic and Synthetic

      Abbreviations

      Acknowledgments

      6.626.1. Introduction

      6.626.2. Native Heart Valve Structure

      6.626.3. Current Treatments

      6.626.4. Ideal Scaffold

      6.626.5. Synthetic Scaffolds

      6.626.6. Decellularized Heart Valve Scaffolds

      6.626.7. Naturally Derived Biomaterials of Nonvalvular Origin

      6.626.8. Conclusion

      6.627. Drug-Eluting Stents

      Abbreviations

      6.627.1. Introduction

      6.627.2. The Need for Coronary Stents: Problems with Baloon Angioplasty and Bare-Metal Stents

      6.627.3. Development of DESs

      6.627.4. First Generation DESs

      6.627.5. Benefits of DES

      6.627.6. Risks of DES

      6.627.7. Second Generation DES

      6.627.8. New Drug-Eluting Stents

      6.627.9. Less Successful Medications on DES

      6.627.10. Conclusions

      6.628. Vascular Grafts

      Abbreviations

      6.628.1. Introduction

      6.628.2. Materials Used for Vascular Grafts: Current Clinical Experience

      6.628.3. Host Responses to Implanted Biomaterials

      6.628.4. Improving Clinical Outcomes and Future Concepts

      6.628.5. Gene Therapy

      6.628.6. Tissue-Engineered Blood Vessels

      6.629. Cerebrospinal Fluid Shunts

      Abbreviations

      6.629.1. Introduction

      6.629.2. Hydrocephalus

      6.629.3. Treatment of Hydrocephalus

      6.629.4. Biocompatibility of Silicone Shunts

      6.629.5. Infective Complications

      6.629.6. Treatment of Shunt Infections

      6.629.7. Prevention of Shunt Infections

      6.629.8. Antimicrobial Shunt Catheters

      6.629.9. Evaluation of Antimicrobial Catheters

      6.629.10. Application of In Vitro Tests to Existing Shunt and EVD catheters

      6.629.11. Clinical Studies on Antimicrobial Shunt and EVD catheters

      6.629.12. Conclusions

      6.630. Biomaterials for Spinal Cord Repair

      Abbreviations

      6.630.1. An Introduction to Spinal Cord Injury

      6.630.2. Biomaterials for Drug Delivery

      6.630.3. Biomaterials for Cell Delivery

      6.630.4. Future Outlook

      6.631. Keratoprostheses

      Abbreviations

      6.631.1. The Cornea and the Need for Corneal Replacement

      6.631.2. Conclusion

      6.632. Retina Reconstruction

      Abbreviations

      6.632.1. The Retina

      6.632.2. Ocular Diseases Associated with Retinal Degeneration

      6.632.3. Retinal Reconstruction

      6.632.4. Challenges in Retina Reconstruction

      6.632.5. Scaffold Biocompatibility

      6.632.6. Scaffold Fabrication

      6.632.7. Conclusions

      6.633. Development of Contact Lenses from a Biomaterial Point of View – Materials, Manufacture, and Clinical Application

      Abbreviations

      6.633.1. Introduction

      6.633.2. General Properties of Hydrogel Materials of Relevance to Contact Lenses

      6.633.3. Conventional Hydrogel Contact Lens Materials

      6.633.4. Silicone Hydrogel Contact Lens Materials

      6.633.5. Classification of Soft Contact Lens Materials

      6.633.6. Soft Contact Lens Manufacture

      6.633.7. Clinical Ramifications of Polymer and Manufacturing Developments

      6.633.8. Conclusions

      Appendix A. Classification of Soft Lens Materials

      6.634. Bioartificial Kidney

      Abbreviations

      6.634.1. Overview of Renal Replacement

      6.634.2. Membranes for Small-Solute Clearance

      6.634.3. Renal Epithelial Cell Therapy

      6.634.4. Preclinical Evaluation of Bioartificial Kidney

      6.634.5. Clinical Evaluation of Bioartificial Kidney

      6.634.6. Future Prospects

      6.635. Surgical Adhesion and Its Prevention

      Abbreviations

      6.635.1. Introduction

      6.635.2. Formation of Adhesions and Major Areas of Concern

      6.635.3. Barriers to Adhesion: Current Clinical Practice

      6.635.4. Barriers to Adhesion: Current Research

      6.635.5. Uses for Adhesion

      6.635.6. Discussion

      6.636. Suture Material: Conventional and Stimuli Responsive

      Abbreviations

      6.636.1. Introduction

      6.636.2. Properties of Suture Materials

      6.636.3. Sutures

      6.636.4. Staples

      6.636.5. Surgical Needles

      6.636.6. Conclusions

      6.637. Staple Line Reinforcement Materials

      Abbreviations

      6.637.1. Introduction

      6.637.2. Staple Line Reinforcement

      6.637.3. Reinforcement Materials

      6.637.4. Discussion

      6.638. Biomaterials for Hernia Repair

      6.638.1. Introduction

      6.638.2. History of Biomaterials in Hernia Surgery

      6.638.3. Materials Used in Hernia Surgery

      6.638.4. Hernia Surgery with Prostheses

      6.638.5. Forces Acting on Hernia Meshes

      6.638.6. Requirements for Hernia Meshes

      6.638.7. Mesh Fixations

      6.638.8. Potential Complications of Hernia Meshes

      6.638.9. Conclusion and Future Perspectives

      Quotes and reviews

      "In a highly technical and vastly broad subject area, the key to managing (mastering) reputable information and facilitating new breakthroughs is through its preservation and organization by experts in the field. For students or researchers wanting a quick introduction or a working knowledge of an unfamiliar subfield of biomaterials, the assembled chapters will be much more valuable than the typical documents that rise to the top of keyword searches. The authors and editors should be commended for their efforts and congratulated on producing an impressive reference of lasting value. In this reviewer's opinion, it will be an essential reference for any library affiliated with graduate programs in the biomedical sciences. Summing Up: Highly recommended. Upper-division undergraduates and above."--CHOICE

      "[T]his is a huge body of work and I would suspect the price would preclude individual researchers from acquiring the set; however, this is a must have for libraries as an up-to-date reference for the current state-of–the-art information in this field as well as a fundamental reference tome for researchers seeking an introduction to the field."--Journal of Biomaterials Applications, Vol. 26, February 2012, page 761

       
       
      Free Shipping
      Shop with Confidence

      Free Shipping around the world
      ▪ Broad range of products
      ▪ 30 days return policy
      FAQ

      Contact Us